Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia and a leading cause of stroke, heart failure, and reduced quality of life. Structural remodeling of the atria, inflammation, and metabolic stress are major contributors to AFib development.

The Atrial Fibrillation-Dx service interprets CARMD-Dx biomarker results to identify molecular signatures of atrial stress, immune activity, and cardioembolic risk. This empowers clinicians to detect AFib risk earlier, personalize care strategies, and monitor disease progression.

Why This Test Matters

Key Benefits

Standard scans can miss early atrial and vascular changes. Atrial Fibrillation-Dx detects these disruptions at the molecular level so patients and clinicians can act early.

Early Detection

Identifies molecular markers of atrial remodeling before AFib symptoms develop.

Stroke Prevention

Highlights biomarkers linked to cardioembolic risk.

Precision Care

Supports treatment decisions on anticoagulation, rhythm control, and ablation strategies.

Long-Term Monitoring

Tracks changes in atrial stress and inflammation over time.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Atrial Fibrillation-Dx panel measures a targeted range of biomarkers to detect subtle atrial, metabolic, and vascular changes:

  • Atrial stretch and remodeling proteins (natriuretic peptides, ANP/BNP)

  • Inflammatory cytokines (IL-6, CRP, TNF-α)

  • Endothelial dysfunction proteins (VCAM-1, ICAM-1)

  • Coagulation markers linked to embolic risk (D-dimer, fibrinogen)

  • Oxidative stress and myocardial injury markers (troponins, ROS indicators)

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers through the Persona Biomed secure portal.

02

Sample Collection

Blood draw at a certified lab or via mobile phlebotomy.

03

Laboratory Analysis

Biomarker assays evaluate atrial stress, inflammation, and embolic risk.

04

Results Delivery

Comprehensive report delivered in the patient portal with physician-ready interpretation and AI-supported summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with suspected or confirmed atrial fibrillation.

  • Individuals with risk factors such as hypertension, diabetes, obesity, or family history of AFib.

  • Patients with unexplained palpitations, fatigue, or shortness of breath.

  • Individuals at risk of stroke who need biomarker-based risk assessment.

Register Now for
Atrial Fibrillation-Dx

Register now for Atrial Fibrillation-Dx to detect arrhythmia risk early and take proactive steps to prevent complications.

Register now